49 results about "Cholesterol metabolism" patented technology

The invention discloses a tumor cholesterol metabolism regulation microneedle patch and a preparation method, the microneedle patch comprises a needle tip and a backing which are connected, the needle tip comprises a needle tip body and nanoparticles loaded on the needle tip body, the nanoparticle is a manganese ion-doped organic metal framework, the outer layer of the manganese ion-doped organic metal framework is modified with a targeting agent, cholesterol oxidase and superoxide dismutase are carried on the manganese ion-doped organic metal framework, the targeting agent can target a CD44 receptor, and the organic metal framework can carry drugs. The targeted drug can enter tumor cells in a targeted mode, superoxide dismutase catalyzes superoxide anions overexpressed in the tumor cells to generate H2O2 and O2, O2 needed by catalysis is provided for cholesterol oxidase, cholesterol at the tumor site is consumed by the cholesterol oxidase, accumulation of 7-DHC is reduced, meanwhile H2O2 can be generated, and the cholesterol oxidase can be used for catalyzing the tumor site. H2O2 is catalyzed by manganese ions through a Fenton-like reaction to generate OH to induce tumor cells to generate ferroptosis, so that ferroptosis-immune synergistic treatment is realized.

The invention provides a composition with a blood sugar reducing function and application thereof, and belongs to the technical field of diabetes treatment. The composition is prepared from burdock root extract, folium ilicis purpurea extract, hypoglycemic decapeptide, trehalose, sodium benzoate, glycerol, vitamin C and water. The composition disclosed by the invention has a multi-target synergistic effect, and by integrating natural plant extracts and functional peptides, multiple targets related to diabetes mellitus are adjusted, so that the blood sugar level is remarkably reduced, and cholesterol metabolism, oxidative damage and inflammatory response are effectively improved. The composition can be used for treating type 2 diabetes mellitus and has a good clinical application prospect.

The invention discloses an effect of an APOA gene in relieving vomitoxin injury of bovine liver cells by vitamin E, and relates to the technical field of the effect of vitamin E in relieving vomitoxin injury of bovine liver cells. The APOA gene refers to an APOA1 gene, an APOA2 gene and an APOA4 gene; the CDS sequence of the APOA1 gene is as shown in SEQ ID NO. 19; the CDS sequence of the APOA2 gene is as shown in SEQ ID NO. 20; the CDS sequence of the APOA4 gene is as shown in SEQ ID NO. 21; the effect is that the vitamin E regulates an APOA gene to be enriched to a cholesterol metabolic pathway. According to the effect of the APOA gene in relieving vomitoxin-caused cattle liver cells, it is found that the vitamin E can effectively protect the cell membrane integrity of the cattle liver cells and can relieve cell viability decline, oxidative stress, inflammatory response and cell apoptosis caused by vomitoxin; vitamin E regulates the cholesterol metabolic pathway by regulating the APOA gene level so as to play a role in protecting liver cells of dairy cows.

Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9. Further provided herein are compositions and methods of treating conditions related to coronary disease.

The invention discloses a highly efficient cholesterol-lowering Lactobacillus paracasei I MAUJBC1 and its application, and relates to the technical field of functional microorganisms. The strain disclosed in the invention can alleviate weight gain caused by a high-fat diet, improve elevated blood lipid levels; reduce the expression level of cholesterol synthesis genes in the liver; significantly increase the expression level of cholesterol metabolism genes in the liver, and play a cholesterol-lowering role; and increase the abundance of beneficial bacteria in the intestinal flora, effectively improve the intestinal flora disorder caused by a high-fat diet, and play a role in alleviating hyperlipidemia.

The invention belongs to the technical field of functional microorganisms, and provides pediococcus acidilactici MR21 and application thereof. The pediococcus acidilactici MR21 provided by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 3, 2024, and the preservation number is CGMCC NO. 32896. The pediococcus acidilactici MR21 disclosed by the invention has efficient in-vitro cholesterol removal capacity, excellent safety and remarkable probiotic characteristics, and has the effects of restoring liver functions, reducing liver fat accumulation and regulating expression of fat and cholesterol metabolism related genes by remarkably reducing the content of serum total cholesterol and low-density lipoprotein cholesterol. Therefore, the function of relieving hypercholesterolemia is achieved.

The invention relates to an SR-B1 targeted polypeptide compound and application thereof in preparation of antitumor drugs and immunotherapy sensitizers, and belongs to the technical field of biological drug manufacturing. In order to solve the problems that an existing PD-L1 inhibitor is single in action mechanism and immune system dysfunction is easily caused, the invention provides an SR-B1 targeted polypeptide compound which is composed of SR-B1 targeted polypeptide and Resiquimod. The SR-B1 targeting polypeptide comprises an SR-B1 targeting peptide fragment, a self-assembly peptide fragment and a hydrophobic molecule which are connected in sequence. The SR-B1 targeting polypeptide can recognize overexpressed SR-B1 in tumor cells, block cholesterol uptake, inhibit tumor progression and inhibit expression of PD-L1 at the same time. The polypeptide compound accurately delivers Resiquimod to a tumor site, anti-tumor immune response is activated, and sensitivity of tumor immunotherapy is greatly enhanced through combination of cholesterol metabolism regulation and immunotherapy.

The invention discloses a sweet potato vine-sourced polypeptide ST2b and application thereof, and belongs to the technical field of biological medicine, the amino acid sequence of the sweet potato vine-sourced polypeptide ST2b is GSFKMEGKR, and the polypeptide ST2b inhibits the occurrence and development of type 2 diabetes mellitus by regulating host cholesterol metabolism, so that the development of type 2 diabetes mellitus is inhibited. Experiments prove that the polypeptide ST2b treatment can inhibit expression of cholesterol synthesis related genes in a host body, so that the cholesterol level in the host body is reduced, and the characteristic of resisting type 2 diabetes mellitus is exerted; the invention provides a novel application for preparing the medicine for the type 2 diabetes mellitus.

Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9.

The invention discloses construction and application of a lipid metabolism related gene Nrf1-453 specific overexpression mouse model, and relates to the technical field of animal models, in particular to the research field of transgenic functional mice and metabolism related fatty liver diseases. According to the animal model disclosed by the invention, a CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) technology is applied to construct a mouse model with Nrf1-453 conditional gene overexpression; the method comprises the following steps of: establishing a liver cell Nrf1-453 specific overexpression mouse model (Nrf1-453 (L)-OE), exploring the effect of a 453 transcript in homeostasis imbalance of cholesterol metabolism through a high cholesterol feed (HCD), and comprehensively and carefully elaborating the effect and molecular mechanism of the subtype in the occurrence and development of MAFLD caused by the HCD. The metabolism-related fatty liver disease animal model prepared by adopting the construction method disclosed by the invention can be used for research on effects and molecular mechanisms in occurrence and development of related diseases and screening and / or evaluation of drugs for the related diseases.

The application relates to the field of biological medicine, in particular to application of TDF in serum cholesterol regulation and a verification method. The application discloses that tenofovir disoproxil fumarate (TDF) can inhibit intestinal cholesterol absorption by specifically down-regulating the expression level of NPC1L1 protein in the intestinal tract, so as to reduce serum cholesterol. The regulation has tissue specificity, and TDF has no significant influence on the expression of key genes of liver cholesterol metabolism. The application also provides a method for verifying the regulation of TDF on serum cholesterol, which is evaluated by detecting blood lipid indexes and the gene and / or protein expression level of NPC1L1 in duodenal tissue. The application provides a treatment scheme with antiviral and cholesterol-lowering effects for patients with chronic hepatitis B combined with hypercholesterolemia, and provides a new idea for developing a lipid-lowering strategy targeting intestinal cholesterol absorption.

The invention discloses a method for researching the influence of exercise training on myelin sheath repair, and relates to the technical field of biology. Comprising the following steps: S1, data collection and analysis: acquiring a spinal cord injury related data set from a GEO database through a bioinformatics method, and determining differential gene expression related to spinal cord injury; carrying out GO enrichment and KEGG function enrichment analysis on the differential genes, taking intersections of the differential genes and cholesterol-related genes, and screening; s2, establishment of an animal model: selecting mice, and randomly dividing the mice into a false operation group and a spinal cord injury group; and constructing a half-side spinal cord injury model for the mice in the spinal cord injury group. The invention provides a new scientific basis and strategy for treatment of spinal cord injury, and particularly emphasizes the importance of exercise training in combination with cholesterol metabolism regulation in promotion of myelin sheath repair; the mechanism of the PGC1 alpha for regulating and controlling the cholesterol metabolic pathway is discussed, and a theoretical basis is provided for exploration in combination with clinical application.

The invention relates to a brand new application of bifidobacterium longum BL21, in particular to an application of the bifidobacterium longum BL21 in preparation of a tumor treatment synergist. The BL21 strain provided by the invention can effectively improve the treatment effect of conventional tumor treatment means such as radiotherapy and / or alphaPD-L1 antibody intervention. Specifically, compared with pure radiotherapy and / or alphaPD-L1 antibody intervention, the intervention of the bifidobacterium longum BL21 can further prolong the survival time of a patient, reduce the tumor growth speed, regulate intestinal microbiota, regulate the cholesterol metabolism level and change the tumor immune microenvironment, and has a prevention effect on cancer cell proliferation.

The invention relates to the technical field of biological medicine, and particularly discloses application of nefenavir. Nefinavir is used for preparing a medicine for treating or preventing castration-resistant prostate cancer, and the medicine can specifically up-regulate expression of DHCR7, induce DNA damage of tumor cells and activate a cell cycle arrest pathway mediated by periodic protein of the cells so as to inhibit key biological processes such as proliferation of the tumor cells, cholesterol metabolism and the like; especially, formation and amplification of multinuclear giant cells in castration-resistant prostate cancer can be effectively inhibited by up-regulating expression of DHCR7, so that malignant progression of multinuclear giant cell mediated tumors and treatment of drug resistance are blocked. Finally, the castration-resistant prostate cancer is prevented and treated, and the technical bottlenecks that an existing castration-resistant prostate cancer treatment means is limited in curative effect, and the drug resistance and metastasis capability mediated by multinuclear giant cells are difficult to inhibit in a targeted manner are solved.

The invention discloses a preparation and research method of Qinghai characteristic blend oil, which comprises the following steps: step 1: by taking rapeseed oil, yak ghee and linseed oil as raw materials, carrying out function optimization to obtain animal and plant blend oil according to the blending proportions of 65.83% of rapeseed oil, 33.06% of linseed oil and 1.11% of yak ghee; and step 2, after optimization, blending to obtain an oleic acid value, a peroxide value, an iodine value, a saturated fatty acid content value and a ratio of monounsaturated fatty acid to polyunsaturated fatty acid of the animal and plant blend. The blend oil prepared by the invention has good thermal stability, can regulate fatty acid synthesis, fatty acid oxidative catabolism and cholesterol metabolic pathways through a regulation mechanism to reduce the fatty acid content in mice, improve the liver fat deposition of high fat diet mice, and improve the immunity of the mice. Theoretical basis and data support are provided for blending the animal and plant blend oil with balanced nutrition, and reference is provided for research and development of the animal and plant blend oil in the future.

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.

Methods of treating diseases and conditions in human subjects in need thereof using pharmaceutical compositions comprising an ANGPTL3 RNAi agent are described, the treatment being partially mediated by reducing expression of the ANGPTL3 gene. When administered to a human subject in need thereof according to the methods disclosed herein, the disclosed pharmaceutical compositions comprising an ANGPTL3RNAi agent treat diseases and conditions associated with elevated triglyceride (TG) levels and / or elevated low density lipoprotein cholesterol (LDL-C), such as hypertriglyceridemia (including severe hypertriglyceridemia (SHTG)), homozygous familial hypercholesterolemia (HoFH), hypertriglyceridemia-induced pancreatitis, metabolic syndrome, obesity, hyperlipidemia, mixed dyslipidemia, abnormal lipid and / or cholesterol metabolism, atherosclerosis, cardiovascular disease, type II diabetes, coronary artery disease, and the like. The present invention relates to compounds of formula (I), in particular to compounds of formula (I), such as non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, heterozygous familial hypercholesterolemia (HeFH), statin-resistant hypercholesterolemia, other dyslipidemia, and other metabolism-related conditions and diseases.

The invention discloses a sound-sensitive bionic nano-drug and a preparation method thereof, and belongs to the technical field of biological medicines. The sound-sensitive bionic nano-drug comprises porphyrin-hybridized hollow mesoporous organic silicon dioxide, a macrophage membrane and a cholesterol metabolism regulating drug, the porphyrin-hybridized hollow mesoporous organic silicon dioxide is a sound-sensitive agent and a carrier, the surface of the outer layer of the hollow mesoporous organic silicon dioxide is coated with the macrophage membrane, and the cholesterol metabolism regulating drug is coated with the macrophage membrane. Tetra (4-carboxyphenyl) porphyrin (TCPP) in a sound-sensitive agent is hybridized on a hollow mesoporous organic silicon dioxide skeleton, Ava is loaded on mesoporous and hollow structures of the TCPP, and the tumor killing effect is improved by regulating cholesterol metabolism of tumor cells and T cells and cooperating with SDT. And the sound-sensitive bionic nano-drug provides a new normal form for tumor treatment through'metabolism-sonodynamic-immunization 'multi-dimensional combination, and breaks through the limitation of traditional single treatment.

This invention belongs to the fields of biomedical materials and colloid chemistry, and discloses a structurally remodeled egg yolk low-density lipoprotein biomimetic liposome and its application in regulating cholesterol metabolism. The method includes extracting and purifying natural egg yolk low-density lipoprotein; selectively removing endogenous cholesterol by adding β-cyclodextrin under alkaline conditions; adding a phytosterol ethanol solution to the cholesterol-removed low-density lipoprotein dispersion, followed by incubation and dialysis purification to obtain the biomimetic liposome. The obtained biomimetic liposome uses partially cholesterol-removed egg yolk low-density lipoprotein as its structural framework, with phytosterols embedded in its phospholipid monolayer and lipid core interface. This biomimetic liposome can inhibit cholesterol micelle formation, reduce cholesterol absorption, promote macrophage cholesterol efflux, and inhibit macrophage foam formation. It can be used to prepare cholesterol metabolism regulating materials, functional delivery systems, and dietary supplement products.

The present invention provides an application of a DHCR7 down-regulator in attenuating alcohol-induced liver tumors. The present invention reveals that DHCR7 plays a role in regulating liver tumors (alcohol-induced liver tumors), analyzes the important mechanism of action of the cholesterol metabolism pathway regulated by DHCR7 in the development of liver tumors, and provides a drug target and theoretical basis for the development of a new generation of anti-cancer drugs. Taking DHCR7 as a target, drugs for inhibiting (including alleviating or treating) liver tumors can be developed, as well as for diagnosing and prognosticating liver tumors or symptoms.

The invention belongs to the field of gene engineering, and particularly relates to application of an SQLE gene in inhibition of PEDV virus replication. The invention provides shRNA (short hairpin Ribonucleic Acid) of a specific targeting SQLE gene, the shRNA can specifically target the SQLE gene, the knock-down of the SQLE gene is realized, and an LLC-PK1 cell line of the knock-down cholesterol metabolism gene SQLE is obtained. The cell line has resistance phenotype to PEDV virus, can significantly inhibit PEDV virus, and is expected to enhance immunogenicity and induce a body to generate stronger immune response, so that PEDV infection is effectively resisted, and the problem of poor immune effect of a traditional vaccine is solved.

The present invention addresses the problem of providing a test substance evaluation method and a test substance evaluation kit with which it is possible to distinguish between damage caused by suppression or deletion of a function of a gene product and damage caused by stimulation in human-derived pluripotent stem cells in which a function of a gene product involved in cholesterol metabolism regulation has been suppressed or deleted or cells differentiated from said human-derived pluripotent stem cells, and to evaluate the effect of the test substance only on damage caused by stimulation. The present invention provides a test substance evaluation method, the method comprising: a step (a) for culturing human-derived pluripotent stem cells in which a function of a gene product involved in cholesterol metabolism regulation has been suppressed or deleted or cells differentiated from said human-derived pluripotent stem cells in a culture medium substantially free of serum and containing sterols; and a step (b) for bringing the human-derived pluripotent stem cells or cells differentiated from the human-derived pluripotent stem cells into contact with a test substance.

The invention belongs to the technical field of biological medicines, and particularly relates to application of resveratrol in preparation of a medicine for preventing or treating gallstone. The resveratrol can regulate liver cholesterol metabolism, reduce bile cholesterol saturation and relieve liver inflammation by up-regulating expression and functions of PPAR gamma in the liver, so that gall-stone formation is remarkably reduced, and related symptoms such as gallbladder dilatation and cholestasis are relieved. Therefore, the invention provides a new medicine for effectively preventing and treating the cholesterol gallstone, and the resveratrol provided by the invention has good clinical application value and application prospect as the medicine for preventing and treating the cholesterol gallstone. The medicine has the advantages of novel action target, reliable curative effect, no toxic or side effect, abundant resources and low price.

The invention provides application of SPPARMs in treatment of atherosclerosis, and belongs to the technical field of biological medicine. An ApoE gene knockout mouse is subjected to high-fat feeding to construct an atherosclerotic mouse model, THP-1 macrophages are exposed to oxidized low-density lipoprotein to construct a macrophage foaming model, INT131 is used for drug administration to an animal model and a cell model, and results show that INT131 can effectively relieve formation of atherosclerotic plaques, and can be used for treating atherosclerotic plaques. The content of AS mouse serum total cholesterol and low-density lipoprotein cholesterol is obviously reduced, and the content of high-density lipoprotein cholesterol is increased. In addition, INT131 can reduce intake of lipid in macrophages, promote cholesterol excretion and cholesterol metabolism, and inhibit formation of foam cells by inhibiting inflammatory response.

The invention discloses a compound lactic acid bacteria composition and application thereof, and belongs to the technical field of microbial medicine. The compound lactic acid bacteria composition is prepared from lactobacillus plantarum (Lactobacillus plantarum) HMPM1006C and lactobacillus curvatus (Lactobacillus curvatus) HMPM1403C, and the ratio of the viable count of the lactobacillus plantarum (Lactobacillus plantarum) HMPM1006C to the viable count of the lactobacillus curvatus (Lactobacillus curvatus) HMPM1403C to the viable count of the lactobacillus plantarum (Lactobacillus plantarum) HMPM1403C is 1 to (0.1 to 3). Through the synergistic effect of multiple target points, absorption of carbohydrates in the intestinal tract can be delayed, insulin sensitivity can be improved, cholesterol metabolism can be promoted, meanwhile, intestinal flora balance is adjusted, inflammatory response is relieved, improvement on type 2 diabetes mellitus and related metabolic diseases is achieved, and the effect is remarkably superior to that of a single strain; a safe and effective new strategy is provided for prevention and adjuvant treatment of metabolic syndrome, type 2 diabetes and obesity.

The invention discloses an application of ABCA1 as a steady-state regulation target of lung cholesterol. By constructing a CYP27A1 gene knockout mouse model and combining molecular biology and RNA (Ribonucleic Acid) sequencing technologies, the invention further discloses a potential relationship between down-regulation of ABCA1 in liver tissues and specific up-regulation of ABCA1 in lung tissues and cholesterol. The research of the invention not only helps to deepen the understanding of the role of the ABCA1 in the lung cholesterol homeostasis, but also provides theoretical support for the prevention and treatment of cholesterol metabolism related diseases, and defines that the ABCA1 can be used as a target spot for regulating and controlling the lung cholesterol homeostasis.

The present invention discloses a tetravalent platinum complex for inhibiting cholesterol metabolism, a preparation method and an application thereof, and belongs to the field of medical technology. The tetravalent platinum complex of the present invention is obtained by connecting and coordinating a cholesterol metabolism inhibitor with a platinum anticancer drug; the platinum anticancer drug includes a cisplatin derivative or an oxaliplatin derivative. The present invention achieves the anti-tumor purpose by introducing a cholesterol regulator into the structure of a platinum drug, and destroying the material and energy basis required for the growth and reproduction of tumor cells by regulating cholesterol metabolism. In the process of regulating cholesterol metabolism, the immune cells in the tumor microenvironment are affected, and the anti-tumor immune response is activated, thereby achieving the purpose of synergistic anti-tumor, while overcoming the drug resistance and systemic toxicity of traditional platinum drugs.

The present application discloses novel compounds, and compositions comprising said compounds, that are effective small-molecule agonists that stimulate overproduction of cytosolic cyclic AMP (cAMP) in Mycobacterium tuberculosis (Mtb) which inhibits cholesterol metabolism. These small-molecule agonists demonstrate potentiation of current tuberculosis (TB) therapeutics, exhibiting potential as a promising new class of agents for the treatment of TB. The application further discloses methods of treatment of TB using compositions comprising the disclosed novel compounds in combination therapy with current TB therapeutics.

Described herein are methods and kits for the use of ANGPTL3, ANGPTL4, ANGPTL8, and / or ANGPTL3 / 8 inhibitors in the field of severe hypertriglyceridemia, particularly for distinguishing complete or partial lipoprotein lipase (LPL) deficiency and assessing LPL bioavailability in subjects. As described, these inhibitors can be used to distinguish subjects with significant basal LPL activity from controls with no or little LPL activity. The inhibitors can also be used to distinguish recurrent from persistent chylomicronemia in subjects with severe hypertriglyceridemia or chylomicronemia. Administration of the inhibitors can also replace post-heparin LPL activity measurement or genotyping in identifying disorders of triglyceride and HDL-cholesterol metabolism.

The present application relates to the technical field of adoptive cell transfer therapy, and particularly, to a cholesterol metabolite-based TCR-T cell preparation and an immunotherapy. In the present application, 7-hydroxy-hydroxylated cholesterol is used for treating T cells, the level of TCR signals is reduced, the memory function of T cells is enhanced, the memory cell proportion of T cells is increased, and therefore, the continuity of killing tumors is improved.